Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design (2011)
- Authors:
- Autor USP: SILVA, CARLOS HENRIQUE TOMICH DE PAULA DA - FCFRP
- Unidade: FCFRP
- DOI: 10.1080/08927022.2011.589052
- Subjects: NEOPLASIAS; QUÍMICA FARMACÊUTICA; PLANEJAMENTO DE FÁRMACOS; MODELAGEM MOLECULAR; HOMOLOGIA
- Language: Inglês
- Imprenta:
- Source:
- Título: Molecular Simulations
- ISSN: 0892-7022
- Volume/Número/Paginação/Ano: v. 37, n. 14, p. 1186-1206, 2011
- Status:
- Artigo possui versão em acesso aberto em repositório (Green Open Access)
- Versão do Documento:
- Versão submetida (Pré-print)
- Acessar versão aberta:
-
ABNT
SEMIGHINI, Evandro P. e TAFT, Carlton A. e SILVA, Carlos Henrique Tomich de Paula da. Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design. Molecular Simulations, v. 37, n. 14, p. 1186-1206, 2011Tradução . . Disponível em: https://doi.org/10.1080/08927022.2011.589052. Acesso em: 31 mar. 2026. -
APA
Semighini, E. P., Taft, C. A., & Silva, C. H. T. de P. da. (2011). Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design. Molecular Simulations, 37( 14), 1186-1206. doi:10.1080/08927022.2011.589052 -
NLM
Semighini EP, Taft CA, Silva CHT de P da. Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design [Internet]. Molecular Simulations. 2011 ; 37( 14): 1186-1206.[citado 2026 mar. 31 ] Available from: https://doi.org/10.1080/08927022.2011.589052 -
Vancouver
Semighini EP, Taft CA, Silva CHT de P da. Homology modelling, virtual screening and molecular dynamics of the MARK3 KA1 domain for cancer drug design [Internet]. Molecular Simulations. 2011 ; 37( 14): 1186-1206.[citado 2026 mar. 31 ] Available from: https://doi.org/10.1080/08927022.2011.589052 - Discovery of potential neurodegenerative inhibitors in Alzheimer’s disease by casein kinase 1 structure-based virtual screening
- Current topics in computer-aided drug design
- Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia
- General aspects of lead finding and optimization in drug discovery
- Sequence and transcriptional study of HNRPK pseudogenes, and expression and molecular modeling analysis of hnRNP K isoforms
- Molecular dynamics, density functional theory, pharmacophore modeling, molecular interaction fields and ADME/tox investigation of novel bioactive compounds interacting with CDK2 surfaces
- Pharmacophore-based drug design of novel potential tau ligands for Alzheimer's disease treatment
- RNA interference in drug discovery
- Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase
- Current basis for discovery and development of aryl hydrocarbon receptor antagonists for experimental and therapeutic use in atherosclerosis
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
Por se tratar de integração com serviço externo, podem existir diferentes versões do trabalho (como preprints ou postprints), que podem diferir da versão publicada.
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
